恒瑞医药(600276) - 2016 Q1 - 季度财报

Financial Performance - Operating revenue for the first quarter reached CNY 2.67 billion, a year-on-year increase of 21.08%[6] - Net profit attributable to shareholders rose by 25.02% to CNY 684.34 million compared to the same period last year[6] - Operating profit for the quarter was RMB 809,105,754.73, up 21.7% from RMB 664,372,526.12 year-over-year[24] - The company reported a total profit of RMB 808,080,260.70, which is a 22.8% increase from RMB 658,102,778.89 year-over-year[24] - Basic earnings per share increased to RMB 0.3510 from RMB 0.2808, reflecting a growth of 25.0%[25] Cash Flow - Cash flow from operating activities increased by 41.16% to CNY 572.25 million[6] - Total cash flow from operating activities was RMB 3,215,814,266.89, a significant rise from RMB 2,313,006,557.50 in the previous year, indicating strong cash generation capabilities[30] - The net cash flow from operating activities for Q1 2016 was ¥572,253,164.96, an increase from ¥405,400,045.23 in the previous year, representing a growth of approximately 41.1%[31] - Total cash inflow from operating activities was ¥3,240,731,311.44, compared to ¥2,333,365,421.50 in the same period last year, indicating a year-over-year increase of about 39.0%[31] - The ending balance of cash and cash equivalents was ¥5,505,327,364.74, compared to ¥3,829,003,974.64 at the end of the previous year, marking an increase of approximately 43.7%[32] Assets and Liabilities - Total assets increased by 6.16% to CNY 12.20 billion compared to the end of the previous year[6] - Total current assets increased to ¥9,986,072,758.71 from ¥9,378,353,701.07, representing a growth of approximately 6.5%[16] - Total non-current assets amounted to ¥2,218,555,061.98, up from ¥2,118,346,700.49, indicating a growth of about 4.0%[17] - Total liabilities decreased slightly to ¥1,152,184,723.50 from ¥1,138,935,026.85, a reduction of about 1.2%[18] - Shareholders' equity increased to ¥11,052,443,097.19 from ¥10,357,765,374.71, reflecting a growth of approximately 6.7%[18] Investment Activities - The company reported a significant increase of 668.74% in cash paid for construction projects, totaling CNY 197.33 million[12] - The cash flow from investment activities showed a net outflow of ¥196,979,345.38, compared to a net outflow of ¥25,590,117.89 in the previous year, indicating a significant increase in investment expenditures[32] - The cash flow from investment activities for the parent company showed a net outflow of ¥169,116,121.43, compared to a net outflow of ¥21,910,546.07 in the previous year, indicating increased investment activity[34] Shareholder Information - The number of shareholders reached 29,023 at the end of the reporting period[11] - The largest shareholder, Jiangsu Hengrui Medicine Group Co., Ltd., holds 24.30% of the shares[11] Future Plans - The company plans to expand its market presence and invest in new product development to drive future growth[19] - The company plans to continue expanding its market presence and investing in new product development to sustain growth momentum in the upcoming quarters[24]